CURRENT ACCREDITATIONS
Obesity Drug Discovery Challenges and Solutions
Preclinical Bottlenecks
-
Muscle vs. Fat Mass: A primary clinical goal is preserving lean muscle while burning adipose tissue; discovering molecules that selectively target fat without causing sarcopenia remains a major biological hurdle
-
Safety Thresholds: Historically, anti-obesity medications have failed post-approval due to adverse effects like neuropsychiatric risks and cardiovascular strain. New mechanisms require stringent, lengthy toxicity tracking.
Solution: The Ob42MC4R(G894C) strain of zebrafish was employed. Mutations in the MC4R gene are the most common genetic (monogenic) cause of severe obesity, affecting about 1% to 5% of severely obese individuals globally. In this model both loss of fat mass and sarcopenia were systematically measured along with neuropsychiatry toxicity.
Clinical & Diagnostic Challenges
-
Tissue-Specific Targeting: Developing drugs that act specifically on central appetite centers while minimizing peripheral adverse effects requires highly advanced receptor modeling.
-
Unmet Needs in Weight Maintenance: The goal is shifting from mere weight reduction to preventing rapid weight regain, which requires entirely new molecular targets and combination therapies
-
Length and Adherence: Because obesity is a chronic relapsing disease, clinical trials require long intervention periods to assess sustained weight loss and evaluate weight regain upon drug cessation.
Solution: A unique ratio was identified to circumvent this challenge. Adiposity to inflammation response were measured, in other words those with high adiposity but low inflammation were eliminated therefore normalizing the heterogeneity effect. Through this method outcomes orient compound were identified.
Target Discovery & Translational Hurdles
-
Adipose Tissue Heterogeneity: Animal models do not perfectly replicate the complex, dynamic expansion and pathological dysfunction of human white adipose tissue.
-
Systemic Homeostasis: The human body possesses an intrinsic, powerful drive to defend its highest body weight by reducing energy expenditure and increasing hunger signals. This biological resistance causes weight-loss plateaus and predisposes patients to weight regain.
-
Long-Term Weight Maintenance: There is a significant gap in current drug development regarding sustained, off-treatment weight maintenance. The majority of clinical trials track weight loss over fixed periods, leaving questions regarding long-term efficacy without continuous medication.
Solution: The screening system was designed to first remove any compounds with off target and neuropsychiatry risks. The compounds were also evaluated for long term potency such as inflammation and pathology along with physiology endpoints. This enabled to screen large library of compounds.